LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Regulatory Role of Long Non-Coding RNAs Defined

By LabMedica International staff writers
Posted on 12 Dec 2017
Image: Intermediate magnification micrograph of a low malignant potential (LMP) mucinous ovarian tumor (Photo courtesy of Wikimedia Commons).
Image: Intermediate magnification micrograph of a low malignant potential (LMP) mucinous ovarian tumor (Photo courtesy of Wikimedia Commons).
The long non-coding RNA DNM3O has been found to regulate the processes that lead to metastasis and the high mortality of ovarian cancer.

Long non-coding RNAs (lncRNAs) are considered to be non-protein coding transcripts longer than 200 nucleotides. This somewhat arbitrary limit distinguishes lncRNAs from small regulatory RNAs such as microRNAs (miRNAs), short interfering RNAs (siRNAs), Piwi-interacting RNAs (piRNAs), small nucleolar RNAs (snoRNAs), and other short RNAs. LncRNAs have been found to be involved in numerous biological roles including imprinting, epigenetic gene regulation, cell cycle and apoptosis, and metastasis and prognosis in solid tumors. Most lncRNAs are expressed only in a few cells rather than whole tissues, or they are expressed at very low levels, making them difficult to study. Their name notwithstanding, long non-coding RNAs (lncRNAs) have been found to actually encode synthesis of small polypeptides that can fine tune the activity of critical cellular components.

This high mortality of ovarian cancer is primarily caused by resistance to therapy and the diagnosis of ovarian cancer after it has already metastasized, which occurs in approximately 80% of patients. Little is understood about the contribution of lncRNA to epithelial-to-mesenchymal transition (EMT), which correlates with metastasis.

Investigators at Thomas Jefferson University (Philadelphia, PA, USA) sought to establish a connection between lncRNAs and EMT in ovarian cancer. To this end, they performed an integrated analysis of more than 700 ovarian cancer molecular profiles, including genomic data sets, from four patient cohorts.

Results published in the November 17, 2017, online edition of the journal Nature Communications revealed a direct link between overexpression of the lncRNAs DNM3OS, MEG3, and MIAT and their reproducible gene regulation in ovarian cancer EMT. Genome-wide mapping showed 73% of MEG3-regulated EMT-linked pathway genes contained MEG3 binding sites. DNM3OS overexpression, but not MEG3 or MIAT, significantly correlated to worse overall patient survival. In contrast, DNM3OS knockdown resulted in altered EMT-linked genes/pathways, mesenchymal-to-epithelial transition, and reduced cell migration and invasion.

“Overexpression of one of the lncRNAs, DNM30S, was significantly correlated with worse overall ovarian cancer patient survival,” said senior author Dr. Christine Eischen, professor of cancer biology at Thomas Jefferson University.

Related Links:
Thomas Jefferson University

New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Pipette
Accumax Smart Series
CBM Analyzer
Complete Blood Morphology (CBM) Analyzer

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more